Cramer said on Mad Money yesterday....
On the flip side, Charles River Laboratories (CRL)can't seem to catch a break. This company reported better than expected results, and the stock was still slammed because the company's competitor PAREXEL (PRXL) reported horrendous results, and took Charles River down with it.
Cramer spoke with Charles River CEO, James Foster to find out what he thinks could happen in the long-term.
This contract research organization not only provides research for well-known biotech companies, they are also testing Tekmira's Ebola drug in the battle to stop the epidemic.
"Drug companies are all about finding novel targets. If they can't find targets they can't develop drugs against them. That's what biotech companies are doing these days, and now with the companies that we are buying we will be able to discover the targets. Things like Ebola will be affected," said Foster.
News 
Market Data 
Discover 
